PDCD1 and melanoma: In recent years, therapeutic regimens relying on the use of immune checkpoint inhibitors (anti- CTLA4, anti-PD1, and anti-LAG3 antibodies) have shown promising results and have therefore become mainstream treatment for advanced melanomas.